<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910618-0009</DOCNO><DOCID>910618-0009.</DOCID><HL>   Technology Brief -- SmithKline Beecham PLC:   Company Plans to Double   Capacity for 2 Antibiotics</HL><DATE>06/18/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   SBE</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><RE>EUROPE (EU)GREAT BRITAIN (UK)WESTERN EUROPE (WEU)</RE><LP>   SmithKline Beecham PLC said it plans to invest nearly $35million over the next 18 months to double production capacityfor its Augmentin and Timentin antibiotics.   The pharmaceutical company said production of potassiumclavulanate, the key ingredient in Augmentin and Timentin,will be expanded at its two United Kingdom plants.</LP><TEXT>   World-wide sales of Augmentin, an oral and injectableantibiotic for common bacterial infections, increased lastyear by 34% to $793 million. Sales of Timentin, an injectableantibiotic used primarily for serious hospital infections,rose last year by 14% to $144 million.</TEXT></DOC>